In this respect, Perez-Ruiz et al., using melanoma and colon carcinoma models, demonstrated that the combined administration of anti-CTLA-4 and anti-PD-1 antibodies with anti-TNFα or etanercept reduced colitis and hepatitis in mice [172]. Here, CTLA4 is linked to melanoma.